Literature DB >> 16551247

Human T cell responses against melanoma.

Thierry Boon1, Pierre G Coulie, Benoît J Van den Eynde, Pierre van der Bruggen.   

Abstract

Many antigens recognized by autologous T lymphocytes have been identified on human melanoma. Melanoma patients usually mount a spontaneous T cell response against their tumor. But at some point, the responder T cells become ineffective, probably because of a local immunosuppressive process occurring at the tumor sites. Therapeutic vaccination of metastatic melanoma patients with these antigens is followed by tumor regressions only in a small minority of the patients. The T cell responses to the vaccines show correlation with the tumor regressions. The local immunosuppression may be the cause of the lack of vaccination effectiveness that is observed in most patients. In patients who do respond to the vaccine, the antivaccine T cells probably succeed in reversing focally this immunosuppression and trigger a broad activation of other antitumor T cells, which proceed to destroy the tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16551247     DOI: 10.1146/annurev.immunol.24.021605.090733

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  223 in total

1.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Matthew Adamow; Brian A Ginsberg; Teresa S Rasalan; Erika Ritter; Humilidad F Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L Terzulli; Deborah Kuk; Katherine S Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A Jungbluth; James P Allison; Lloyd J Old; Jedd D Wolchok; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

Review 2.  Immune predictors of cancer progression.

Authors:  Benjamin Toh; Valerie Chew; Xilei Dai; Karen Khoo; Muly Tham; Lu-En Wai; Sandra Hubert; Sumathy Velumani; Liang Zhi; Caleb Huang; Jean-Pierre Abastado
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides.

Authors:  Katherina Siewert; Joachim Malotka; Naoto Kawakami; Hartmut Wekerle; Reinhard Hohlfeld; Klaus Dornmair
Journal:  Nat Med       Date:  2012-05       Impact factor: 53.440

4.  Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Authors:  Christophe Caux; Laurence Zitvogel
Journal:  Target Oncol       Date:  2012-02-15       Impact factor: 4.493

5.  CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.

Authors:  Andrew McLarnon; Karen P Piper; Oliver C Goodyear; Julie M Arrazi; Premini Mahendra; Mark Cook; Fiona Clark; Guy Pratt; Charles Craddock; Paul A H Moss
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

Review 6.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Authors:  Luc Pilotte; Pierre Larrieu; Vincent Stroobant; Didier Colau; Eduard Dolusic; Raphaël Frédérick; Etienne De Plaen; Catherine Uyttenhove; Johan Wouters; Bernard Masereel; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 8.  Up for Mischief? IL-17/Th17 in the tumour microenvironment.

Authors:  E Maniati; R Soper; T Hagemann
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

9.  Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity.

Authors:  Pravin Kumar; Ardeschir Vahedi-Faridi; Wolfram Saenger; Andreas Ziegler; Barbara Uchanska-Ziegler
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

Review 10.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.